Related references
Note: Only part of the references are listed.Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Inhibition of Pluripotency Networks by the Rb Tumor Suppressor Restricts Reprogramming and Tumorigenesis
Michael S. Kareta et al.
CELL STEM CELL (2015)
A basal stem cell signature identifies aggressive prostate cancer phenotypes
Bryan A. Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
Jason S. Kirk et al.
ONCOTARGET (2015)
Polycomb-mediated silencing in neuroendocrine prostate cancer
Pier-Luc Clermont et al.
CLINICAL EPIGENETICS (2015)
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2014)
Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes
Rahul Aggarwal et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Does the microenvironment influence the cell types of origin for prostate cancer?
Andrew S. Goldstein et al.
GENES & DEVELOPMENT (2013)
Targeting cell cycle and hormone receptor pathways in cancer
C. E. S. Comstock et al.
ONCOGENE (2013)
Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer
Bradley P. Coe et al.
PLOS ONE (2013)
p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia
Jean-Christophe Pignon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Alexandre Puissant et al.
CANCER DISCOVERY (2013)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
David T. Miyamoto et al.
CANCER DISCOVERY (2012)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran et al.
CANCER DISCOVERY (2011)
Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma
J. Wang et al.
ONCOGENE (2010)
Pro-neural transcription factors as cancer markers
Maria Vias et al.
BMC MEDICAL GENOMICS (2008)
Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer
Zongxiang Zhou et al.
CANCER RESEARCH (2006)
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
AP Bracken et al.
EMBO JOURNAL (2003)
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model
PJ Kaplan-Lefko et al.
PROSTATE (2003)
Share Paper
